Cognition Therapeutics Investor Relations Material

Cognition Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing small molecule therapeutics aimed at treating age-related degenerative diseases and disorders affecting the central nervous system and retina. The company's research focuses on developing a portfolio of small molecule product candidates targeting the sigma-2 receptor (S2R) complex. This receptor complex is a crucial regulator of the cellular damage response for conditions such as Alzheimer's disease , dry age-related macular degeneration (dry AMD), geographic atrophy, among others. Cognition Therapeutics is headquartered in Purchase, New York, and its shares are listed on the Nasdaq.